Sana Biotechnology has released initial results from a first-in-human study evaluating its hypoimmune (HIP) technology in type 1 diabetes treatment. The study, conducted in collaboration with Uppsala University Hospital, involved the transplantation of HIP-engineered pancreatic islet cells into a patient with type 1 diabetes. The approach aims to restore insulin production without the use of immunosuppressive therapy.
Key Findings
- Cell Survival and Functionality:
Four weeks after transplantation, the engineered cells showed evidence of survival and functionality. The presence of C-peptide, a biomarker of insulin production, was detected in the patient’s blood. - Insulin Production Response:
Increased C-peptide levels were observed following a mixed meal tolerance test (MMTT), suggesting that the transplanted cells were producing insulin in response to glucose. - Immunoevasion:
The transplanted cells evaded detection by the immune system, avoiding rejection both by the immune response and the autoimmune mechanisms associated with type 1 diabetes. - Safety and Monitoring:
MRI scans confirmed the continued presence of the graft at the transplantation site, and no adverse events were reported during the observation period.
This study provides preliminary data on the potential use of hypoimmune-engineered cells for treating type 1 diabetes. The results suggest the feasibility of cell transplantation without the need for lifelong immunosuppression, a significant barrier in current cell therapy approaches.
This research represents an early step in the exploration of cell therapies for type 1 diabetes and their broader applications in medicine.
